Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R9CF
|
|||
| Former ID |
DNC008845
|
|||
| Drug Name |
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one
|
|||
| Synonyms |
5-(4-Phenoxybutoxy)psoralen; 870653-45-5; UNII-A62C114Q0Q; CHEMBL444449; A62C114Q0Q; 7H-Furo[3,2-g][1]benzopyran-7-one, 4-(4-phenoxybutoxy)-; 4-(4-phenoxybutoxy)furo[3,2-g]chromen-7-one; 7H-Furo(3,2-g)(1)benzopyran-7-one, 4-(4-phenoxybutoxy)-; C21H18O5; 4-(4-Phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one; 7h-furo[3; 4-(4-phenoxybutoxy)-; 2-g][1]benzopyran-7-one; 5-(4-phenoxybutoxy) psoralen; GTPL2554; SCHEMBL2585454; CTK8F0318; DTXSID80461776; 5-(4-phenoxybutoxy)psoralen
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H18O5
|
|||
| Canonical SMILES |
C1=CC=C(C=C1)OCCCCOC2=C3C=CC(=O)OC3=CC4=C2C=CO4
|
|||
| InChI |
1S/C21H18O5/c22-20-9-8-16-19(26-20)14-18-17(10-13-24-18)21(16)25-12-5-4-11-23-15-6-2-1-3-7-15/h1-3,6-10,13-14H,4-5,11-12H2
|
|||
| InChIKey |
KINMYBBFQRSVLL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 870653-45-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Calcium-activated potassium channel (KCN) | Target Info | Inhibitor | [3] |
| Voltage-gated potassium channel Kv1.3 (KCNA3) | Target Info | Inhibitor | [2], [4] | |
| Voltage-gated potassium channel Kv1.5 (KCNA5) | Target Info | Inhibitor | [2] | |
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Voltage gated Potassium channels | |||
| WikiPathways | Potassium Channels | |||
| BDNF signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2554). | |||
| REF 2 | Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6989-92. | |||
| REF 3 | Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304. | |||
| REF 4 | Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. 2005 Nov;68(5):1254-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.